| Talks： |
| CPAP and beyond: The evolving treatment landscape for OSA |
| Name： |
| Professor Peter Cistulli |
| Position： |
| Professor of Sleep Medicine, President-Elect of World Sleep Society |
| Affiliation： |
1. Charles Perkins Centre and Sydney Medical School, The University of Sydney, Camperdown, Sydney, Australia
2. Department of Respiratory and Sleep Medicine, Royal North Shore Hospital, St Leonards, Sydney, Australia
|
| Email： |
|
| Photo： |
 |
| Research Interests： |
| Sleep Medicine, Obstructive Sleep Apnoea, Sleep Disorders |
| Selected Publications： |
1. Sutherland K, Kairaitis K, Yee BJ, Cistulli PA. From CPAP to tailored therapy for obstructive sleep Apnoea. Multidiscip Respir Med. 2018;13:44. doi:10.1186/s40248-018-0157-0.
2. Ou YH, Colpani JT, Cheong CS, et al., Cistulli PA, Lee CH. Mandibular Advancement vs CPAP for Blood Pressure Reduction in Patients With Obstructive Sleep Apnea. J Am Coll Cardiol. 2024;83(18):1760–1772. doi:10.1016/j.jacc.2024.03.359.
3. Cistulli PA, Sutherland K. Phenotyping obstructive sleep apnoea—Bringing precision to oral appliance therapy. J Oral Rehabil. 2019;46:1185–1191.
|
| Abstract： |
Obstructive sleep apnea (OSA) is increasingly recognised as a heterogeneous disorder, with substantial variation in underlying pathophysiology, clinical presentation, comorbidities, and response to treatment. Continuous positive airway pressure (CPAP) remains the most efficacious and widely used therapy, particularly for moderate-to-severe OSA, but its real-world effectiveness is influenced by patient acceptance and long-term adherence.
The therapeutic landscape is now expanding rapidly. Oral appliance therapy, positional approaches, weight management and emerging metabolic pharmacotherapy, upper-airway surgery, hypoglossal nerve stimulation, and novel pharmacological therapies provide increasing opportunities to individualise treatment. Advances in OSA phenotyping and endotyping may further enable treatment to be matched to the mechanisms driving disease in an individual patient.
This presentation will review these developments and consider how OSA management can evolve from a predominantly CPAP-centred model toward a personalised, multimodal approach that integrates treatment efficacy, patient preference, comorbidity, and long-term clinical outcomes.
|
| 2026年會： |
|
|